Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants
US9278125B2 · kind B2 · utility
7Cited by
13References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 28, 2013 |
| Grant date | Mar 8, 2016 |
| Priority date | — |
| Expiry date | Oct 28, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are pharmaceutical compositions comprising Plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range Plasmodium and analogues of α-galactosylceramide (α-GalCer), a ligand for natural killer T (NKT) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria. Methods of use are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.